Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.

In Korean women, a westernized lifestyle is associated with an increased risk of breast cancer. Fertility preservation has become an increasingly important issue for women with breast cancer, in accordance with substantial improvements in survival rate after cancer treatment. The methods of controlled ovarian hyperstimulation (COH) for fertility preservation in breast cancer patients have been modified to include aromatase inhibitors to reduce the potential harm associated with increased estradiol levels. Random-start COH and dual ovarian stimulation are feasible options to reduce the total duration of fertility preservation treatment and to efficiently collect oocytes or embryos. Using a gonadotropin-releasing hormone agonist as a trigger may improve cycle outcomes in breast cancer patients undergoing COH for fertility preservation. In young breast cancer patients with BRCA mutations, especially BRCA1 mutations, the possibility of diminished ovarian reserve may be considered, although further studies are necessary. Herein, we review the current literature on the practical issues surrounding COH for fertility preservation in women with breast cancer.

Introduction

Breast cancer is the most common cancer in women, and one in five patients are younger than 45 years old at diagnosis [1]. In light of substantial improvements in cancer treatment, fertility preservation has become an increasing priority for women with breast cancer [2,3]. In the United States, the overall 5-year survival rate in women with breast cancer has increased from 74.6% in 1975–1979 to 91.0% in 2007 [4].

A westernized diet, early menarche or late menopause, delayed marriage, and having fewer children later in life are all associated with the increasing risk of breast cancer that has been observed among Korean women. Since 1996, the proportion of early-stage breast cancers has significantly increased, and the incidence rate of female breast cancer was 67.2 cases per 100,000 women in 2010 [5]. Breast cancer is currently the second most common cancer in Korean women, after thyroid cancer. The current methods of controlled ovarian hyperstimulation (COH) for fertility preservation in breast cancer patients have been modified. To reduce the risks associated with increased estradiol levels, aromatase inhibitors (AIs) are co-administered, unlike in other cancers. In contrast to typical infertility treatment, random-start ovarian stimulation is used to minimize the time typically required for fertility preservation treatment prior to chemotherapy.

The Korean Society for Fertility Preservation has suggested that an appropriate method of fertility preservation should be decided through individual patient counseling. Methods such as the cryopreservation of embryos, oocytes, or ovarian tissue and gonadotropin-releasing hormone (GnRH) agonist treatment during chemotherapy may be considered, and patients must consult with experts before chemotherapy or any other treatment [6]. Herein, practical concerns related to fertility preservation in women with breast cancer will be discussed. With this review, we aim to provide useful clinical information based on recent studies.

Letrozole administration during ovarian stimulation

Estrogen exposure is a well-known risk factor for estrogen receptor (ER)-positive breast cancer [7,8]. The role of estrogen in the carcinogenesis of ER-negative breast cancer has yet to be elucidated, and estrogens are thought to have little effect on breast carcinogenesis in ER-negative breast cancer [9]. However, several studies have suggested a possible association between estrogen-dependent reproductive characteristics such as high parity and the incidence of ER-negative breast cancer [10,11]. Therefore, treatment with letrozole may be useful even in patients with ER-negative breast cancer.

Letrozole is an AI that prevents estrogen production through competitive, reversible binding to the heme of the cytochrome P450 unit of aromatase [12]. Clinically, 5 mg/day letrozole (Femara; Novartis, East Hanover, NJ, USA) is administered on day 2 or 3 of the patient’s cycle. The administration of letrozole is continued daily during COH and discontinued on the day of the trigger. After oocyte retrieval, letrozole is continued again for approximately 3 to 6 days until estradiol levels decrease to <50 pg/mL [13].

Evidence suggests that the administration of letrozole during COH can significantly reduce peak estradiol concentrations. Peak estradiol concentrations (337–829 pg/mL) were found to be less than 1,000 pg/mL when letrozole was commenced on days 2–3 [14-18]. However, Azim et al. [19] reported that anastrozole did not suppress estradiol at its maximum tolerated oral dose of 10 mg/day compared to 5 mg/day of letrozole (2,515.07±1,368.52 vs. 714±440.83 pg/mL, respectively; p=0.01), and letrozole was more potent than anastrozole for the suppression of estrogen.

While it potentially avoids the negative effects of estrogens on tumor growth, letrozole prevents the aromatization of androgens to estrogens, which may induce significant changes in the endocrine follicular environment and impact oocyte competence. Several studies have investigated whether the co-administration of letrozole has an impact on oocyte yield. Oktay et al. [16] and Checa Vizcaino et al. [20] both reported that oocyte yield was not significantly affected when letrozole was administered. In contrast, Domingo et al. [17] and Revelli et al. [18] demonstrated a small but significant decrease in oocyte yield . The administration of letrozole with gonadotropins significantly reduced the number of oocytes available for cryostorage in comparison with the use of gonadotropins alone in breast cancer patients [18]. The triggering of ovulation with a gonadotropin-releasing hormone agonist (GnRHa) has been suggested to help minimize its negative effect [21], and in vitro maturation is a useful strategy to improve the mature oocyte yield in breast cancer patients undergoing ovarian stimulation for fertility preservation [15].

A recent systematic review identified 1,002 records, of which 15 selected studies were included in the final analysis [22]. No evidence was found of a decline in relapse-free survival rates in women with breast cancer who received COH with the coadministration of letrozole compared with women who did not undergo fertility preservation procedures. Kim et al. [23] reported the largest long-term study, including over 5 years of safety data, regarding the use of COH with letrozole supplementation for fertility preservation via embryo or oocyte cryopreservation in women with breast cancer. The mean follow-up duration after diagnosis was 5.0 years in the fertility preservation group and 6.9 years among the control patients, who chose not to undergo fertility preservation. In the fertility preservation group, the hazard ratio for recurrence after ovarian stimulation was 0.77 (95% confidence interval, 0.28–2.13), and survival was not compromised compared with controls (p=0.61). Neither BRCA gene mutation status (p=0.57) nor whether fertility preservation was undergone before or after breast surgery (p=0.44) significantly affected survival outcomes in the fertility preservation group. None of the tumor characteristics, including ER status, affected the survival rates after COH with letrozole supplementation [23]. COH with concurrent use of AIs appeared to be a safe fertility preservation option for young women with breast cancer at risk of fertility loss following chemotherapy.

Tamoxifen, sold under the brand name Nolvadex among others, is a selective ER modulator. It is a nonsteroidal triphenylethylene antiestrogen. In breast cancer patients, tamoxifen has been proven to have an excellent suppressive effect on cancer cell proliferation and tumorigenesis. Tamoxifen is often preferred over other treatments, as it does not antagonize endometrial development. Oktay et al. [14] compared tamoxifen and letrozole during COH for embryo cryopreservation in breast cancer patients. They used 60 mg/day of tamoxifen alone (Tam-in vitro fertilization [IVF]), 60 mg/day of tamoxifen in combination with low-dose follicle-stimulating hormone (FSH; TamFSH-IVF), or 5 mg of letrozole in combination with FSH (letrozole-IVF). The combination of low-dose FSH with tamoxifen (TamFSH-IVF) or letrozole (letrozole-IVF) resulted in higher embryo yields than Tam-IVF. The recurrence rates did not appear to be higher, but the letrozole protocol may be preferred due to lower peak estradiol levels. However, due to insufficient data, conclusions could not be drawn regarding the use of tamoxifen in women with breast cancer during COH [20,24]. Several relevant studies of AI or tamoxifen administration during COH in women with breast cancer are summarized in Table 1.

Table 1.

Summary of studies involving aromatase inhibitor/tamoxifen administration during ovarian stimulation in women with breast cancer

Study	Study design	Protocol	Peak estradiol (pg/mL)	Oocyte outcome
Kim et al. (2016) [23]	Prospective, non-randomized, controlled study	Letrozole (5 mg)+150–300 U of FSH daily	564.5±436.3	13.3±8.4
	-120 Women: COH prior to surgery, 14 patients; postoperative COH, 106 patients
	-217 Women: no COH
Meirow et al. (2014) [24]	Prospective consecutive enrollment	ER− group: COH with variable dose of FSH	COH vs. COH+tamoxifen: 5,093±4,364 vs. 6,924±4,146 (p=0.095)	COH vs. COH+tamoxifen: 10.2±6.1 vs. 12.7±8.0 (p=0.183)
	-27 Women with ER− breast cancer: COH	ER+ group: COH with variable dose of FSH+tamoxifen (20 mg) daily
	-43 Women with ER+ breast cancer: COH+ tamoxifen
Revelli et al. (2013) [18]	Retrospective cohort study	Letrozole (5 mg)+FSH daily	FSH+letrozole vs. FSH only: 446±357 vs. 1,553±908 (p=0.001)	FSH+letrozole vs. FSH only: 6.6±3.5 vs. 8.0±5.0 (p=0.038)
	-50 Women with ER+ breast cancer: FSH+letrozole
	- 25 Women with ER− breast cancer: FSH only
Domingo et al. (2012) [17]	Retrospective multi-center study	Women with breast cancer: FSH+letrozole (5 mg)+150–225 U of FSH daily	FSH+letrozole vs. FSH only (non-breast cancer) vs. FSH only (male factor): 381±191 vs. 1,744±1,242 vs. 2,109±1,260 (p<0.001)	FSH+letrozole vs. FSH only (non-breast cancer) vs. FSH only (male factor): 9.8±7.1 vs. 12.2±6.5 vs. 12.4±5.4 (p=0.003)
	-142 Women with breast cancer: FSH+letrozole	Women with non-breast cancer: 150–225 U/day of FSH only
	-66 Women with non-breast cancer: FSH only	Women without cancer: 150–225 U/day of FSH only
	-97 Women without cancer (male factor infertility): FSH only
Checa Vizcaino et al. (2012) [20]	Prospective data collection, retrospective analysis	Women with breast cancer: letrozole (5 mg)+150–225 U of FSH daily	FSH+letrozole vs. FSH only: 829±551.11 vs. 1,666.4±739.42 (p=0.006)	FSH+letrozole vs. FSH only: 16.3±7.21 vs. 15.4±8.19 (no significant difference)
	-9 Women with breast cancer, FSH+letrozole	Women with non-breast cancer: 150–225 U/day of FSH only
	-10 Women with non-breast cancer, FSH only
Azim et al. (2007) [19]	Prospective sequential cohort study	FSH+letrozole: letrozole (5 mg)+FSH daily	FSH+letrozole vs. FSH+anastrozole: 714.38±440.83 vs. 2,515.07±1,368.52 (p=0.01)	FSH+letrozole vs. FSH+ anastrozole: 11.57±7.14 vs. 9.71±8.5 (no significant difference)
	-47 Women, FSH+letrozole	FSH+anastrozole: maximum tolerated dose of 10 mg of anastrozole+FSH daily
	-7 Women FSH+anastrozole
Oktay et al. (2006) [16]	Prospectively recruited women with breast cancer compared with retrospectively identified age-matched controls who underwent IVF to treat tubal disease	FSH+letrozole: letrozole (5 mg)+150–300 U of FSH daily	FSH+letrozole vs. FSH only: 483.4±278.9 vs. 1,464±664.9 (p<0.001)	FSH+letrozole vs. FSH only: 8.7±4.8 vs. 9.7±5.1 (p=0.43)
	-47 Women with breast cancer, FSH+letrozole	FSH only: 300 U of FSH daily
	-56 Women with tubal disease, FSH only
Oktay et al. (2005) [14]	Prospective cohort study	TamOnly: tamoxifen (60 mg) daily	TamOnly vs.TamFSH: 419±39 vs. 1,182±271 (p<0.05)	TamOnly vs.TamFSH: 1.5±0.3 vs. 5.1±1.1(p<0.05)
			TamOnly vs. LetFSH: 419±39 vs. 380±57 (p>0.05)	TamOnly vs. LetFSH: 1.5±0.3 vs. 8.5±1.6 (p<0.001)
			TamFSH vs. LetFSH: 1,182±271 vs. 380±57 (p<0.05)	TamFSH vs. LetFSH: 5.1±1.1 vs. 8.5±1.6 (p>0.5)
	-12 Women, tamoxifen only IVF (TamOnly)	TamFSH: FSH (150 U)+tamoxifen (60 mg) daily
	-7 Women, FSH+tamoxifen IVF (TamFSH)	LetFSH: letrozole (5 mg)+FSH (150 U) daily
	-11 Women, FSH+letrozole IVF (LetFSH)

COH, controlled ovarian hyperstimulation; FSH, follicle-stimulating hormone; ER, estrogen receptor; IVF, in vitro fertilization.

Random-start ovarian stimulation

Traditionally, ovarian stimulation is initiated in the early follicular phase within 3 days of the period before dominant follicle selection. The rationale for this timing includes the stimulation of a synchronous cohort of antral follicles recruited during the interfollicular transition and the induction of timely endometrial development to synchronize blastocyst development with the implantation window. However, the synchronization of endometrial development is not required if the aim of the cycle is oocyte or embryo cryopreservation for fertility preservation without fresh embryo transfer (ET) for immediate pregnancy. This is particularly pertinent in cases subject to time constraints, such as those of cancer patients awaiting gonadotoxic chemotherapy.

After an early referral to a fertility specialist, the prompt use of COH instead of the conventional protocol is very important in all reproductive-aged women undergoing cancer treatment who desire fertility preservation. To provide optimal cancer treatment with minimal delay, random-start ovarian stimulation can be performed. In patients with breast cancer who undergo surgical resection as the first step of cancer therapy, COH begins immediately for a 4- to 6-week window between surgery and adjuvant chemotherapy. Therefore, the conventional initiation of COH within 3 days of the period is impossible, and random-start ovarian stimulation can be used at the initial visit. COH can be initiated before and/or immediately after surgery. Oocyte or embryo cryopreservation can be accomplished with random-start COH within 2–3 weeks, and patients can proceed subsequently with surgery or additional cancer treatment such as chemotherapy, radiation, and/or hormonal therapy [25].

A GnRH antagonist can be administered to pause the patient’s cycle, and this approach has been shown to have no negative impact on embryo quality and to improve synchronous follicular growth in poor responders [26]. The appropriate use of a GnRH antagonist can accomplish random-start COH regardless of the point in the menstrual cycle. In a prior study, ovarian stimulation without a GnRH antagonist was initiated if the follicle cohort following the lead follicle was smaller than 12 mm and remained smaller than 12 mm prior to a spontaneous luteinizing hormone (LH) surge. After an LH surge, administration of a GnRH antagonist was initiated when the secondary follicle cohort reached 12 mm to prevent a premature secondary LH surge. If the follicle cohort following the lead follicle reached 12 mm before the spontaneous LH surge, pituitary suppression with a GnRH antagonist was initiated and continued until the triggering of final oocyte maturation. Ovulation was induced with human chorionic gonadotropin (hCG) or a GnRH agonist when the dominant follicle reached 18 mm in diameter, and ovarian stimulation was initiated 2–3 days into the luteal phase [27]. To downregulate LH and initiate luteolysis, a GnRH antagonist was administered with recombinant FSH while simultaneously initiating follicular stimulation.

Martinez et al. [28] published the largest study reporting the outcomes of different random-start protocols with and without AIs. According to that study, random-start ovarian stimulation provided a significant advantage by decreasing the total time for an IVF cycle, and in emergent settings, ovarian stimulation can be initiated at a random cycle date for fertility preservation without compromising oocyte yield or maturity. Although random-start COH protocols are efficient in obtaining an appropriate number of mature oocytes/embryos, only a minority of the patients underwent thawing and ET, and not enough reports have been conducted to evaluate the rates of implantation and pregnancy. Nevertheless, comparable pregnancy rates after the transfer of embryos created from donor eggs obtained after luteal-phase start protocols are encouraging.

Danis et al. [29] published a systematic review of 19 studies published between January 2000 and June 2017 to evaluate the utility of random-start ovarian stimulation for fertility preservation. This recent review suggested that random-start stimulation was associated with a reduced time interval between the initiation of ovarian stimulation and oocyte or embryo cryopreservation. The yield of mature oocytes and their potential development into embryos was comparable between the conventional and random-start protocols, although the gonadotropin doses were higher in the random-start protocols.

Therefore, additional clinical studies are necessary to further assess the efficacy of this strategy, especially regarding the rates of clinical pregnancy and live-born infants originating from the use of cryopreserved embryos and oocytes obtained via random-start ovarian stimulation.

Dual ovarian stimulation

Dual ovarian stimulation consists of two successive instances of ovarian stimulation in the follicular and ensuing luteal phase, with oocyte retrieval at the end of each ovarian stimulation. Evidence is accumulating that follicular- and luteal-phase COH is feasible in patients with poor prognoses with a reduced ovarian reserve to increase their chances of conceiving in each menstrual cycle [30-32].

Kuang et al. [30] investigated the efficiency of dual ovarian stimulation with a combination of gonadotropins, clomiphene citrate, and AI in the follicular and luteal phases in patients with poor ovarian response. In this pilot study, the first stimulation was conducted using a combination of 25 mg per day of clomiphene citrate starting on day 3 of the cycle until ovulation was triggered, 2.5 mg of letrozole per day starting on day 3 for a total of 4 days, and 150 IU of human menopausal gonadotropin (hMG) every other day starting on day 6 until the triggering of ovulation. The second stimulation was initiated after the first oocyte retrieval, provided that two or more antral follicles were identified, and it consisted of 2.5 mg of letrozole and 225 IU/day of hMG, which were both administered from the day of retrieval until the second trigger of ovulation. A relatively large dose of hMG was used to perform ovarian stimulation after the first oocyte retrieval due to the ovarian insensitivity to hMG stimulation during the luteal phase relative to the follicular phase. For both the first and second stimulations, final oocyte maturation was induced with a GnRH agonist (triptorelin, 100 µg) when follicular maturation was reached. The authors reported similar developmental potential for the antral follicles from the luteal phase compared with those from the follicular phase in terms of mature oocytes, fertilization rate, cleavage rate, and the number of top-quality embryos obtained [30].

In a more recent prospective paired non-inferiority observational study, Ubaldi et al. [31] reported a similar number of euploid blastocysts per metaphase II oocyte injected after follicular- and luteal-phase COH in the same menstrual cycle. In follicular-phase COH versus luteal-phase COH, no differences were observed in the number of retrieved cumulus-oocyte complexes (5.1±3.4 vs. 5.7±3.3, respectively), metaphase II oocytes (3.4±1.9 vs. 4.1±2.5, respectively), biopsied blastocysts (1.2±1.2 vs. 1.4±1.7, respectively), or euploid blastocysts (0.6±0.8 vs. 0.7±0.8, respectively). The types of chromosomal abnormalities observed in aneuploid embryos from the follicular-phase COH and luteal-phase COH were also similar, suggesting no impact on the meiotic maturation of oocytes.

Two studies were recently published and reported promising results of double ovarian stimulation [32,33]. Cardoso et al. [33] conducted a retrospective and comparative study of 13 patients who underwent unsuccessful IVF cycles with a conventional antagonist ovarian stimulation protocol and repeated the attempt with a double stimulation protocol. They used the conventional ovarian stimulation antagonist protocol involving a high dose of gonadotropins (225 IU of FSH and 75 IU of hMG), and the triggering was carried out with a single subcutaneous injection of hCG (250 μg). The ovarian double stimulation protocol was similar to the conventional protocol, except triggering was initiated using a GnRH agonist (triptorelin, 0.2 mg). The patients subjected to dual ovarian stimulation exhibited a statistically significant increase in the mean number of oocytes collected, from 5.3 to 9.3 mature oocytes [33].

Liu et al. [34] conducted a retrospective case-control study involving a total of 116 women aged ≥38 years who were treated with double ovarian stimulation. The women were divided into 4 groups according to the follicular-phase ovarian stimulation protocol: a GnRH agonist short protocol, a GnRH antagonist protocol, a mild stimulation protocol, and a progestin pituitary downregulation protocol. The starting dose of gonadotropin was 150–300 IU of FSH, and luteal phase stimulation was performed with 225 IU of hMG daily within 1–3 days of oocyte retrieval. Both instances of triggering were performed using 250 IU of hCG. The numbers of oocytes retrieved and metaphase II oocytes (p=0.002 and p=0.003, respectively), fertilized oocytes (p=0.003), cleaved embryos (p=0.002), and top-quality embryos (p=0.031) with luteal-phase stimulation were higher than those retrieved with follicular-phase stimulation [34].

The first study that investigated stimulation with an identical protocol in the follicular and luteal phases of the same menstrual cycle found a similar number of euploid blastocysts in patients with reduced ovarian response. The evidence of multiple follicular waves during a single menstrual cycle in women with diminished ovarian reserve raised important implications. In particular, it indicated that random-start COH offers an efficient strategy for fertility preservation in young cancer survivors to save time before anticancer therapies. Dual stimulation can maximize the number of oocytes obtained per menstrual cycle and in turn increases the chance of obtaining reproductively competent embryos in the shortest possible time. Randomized controlled trials comparing pregnancy outcomes after dual stimulation are eagerly awaited [35].

In a retrospective observational study that involved 50 cycles in 34 patients who underwent fertility preservation due to breast cancer, follicular-phase or luteal-phase ovarian stimulation with an AI was performed. The numbers of oocytes retrieved at the first and second oocyte pickup did not differ significantly between conventional stimulation and dual stimulation. The researchers demonstrated the efficacy of luteal-phase stimulation and dual stimulation with the AI protocol among breast cancer patients in regard to increasing the number of oocytes harvested within the limited time available before the initiation of cancer treatment [36].

Triggering with GnRHa versus hCG

Reddy et al. [37] compared the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS) when oocyte maturation was triggered by a GnRHa versus hCG in breast cancer patients undergoing fertility preservation. A total of 129 women aged ≤45 years, diagnosed with stage ≤3 breast cancer, and with normal ovarian reserve who desired fertility preservation were compared in the retrospective cohort study. COH was achieved utilizing letrozole and gonadotropins. Serum anti-Müllerian hormone (AMH) levels were similar between the GnRHa and hCG groups (2.7±1.9 vs. 2.1±1.8 ng/mL, respectively; p=0.327). One case of mild or moderate OHSS was reported in the GnRHa group compared to 12 in the hCG group (2.1% vs. 14.4%, respectively; p=0.032). The maturation and fertilization rates and the number of cryopreserved embryos were significantly higher in the GnRHa group. Therefore, the researchers suggested that the GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancer patients undergoing fertility preservation [37].

A GnRHa trigger can be effective in the induction of oocyte maturation and prevention of OHSS on IVF cycles using an antagonist protocol. Yilmaz et al. [38] reported the comparison of different triggers in different cycles of the same patients. The authors reasoned that the GnRHa trigger is clinically more successful than hCG with regard to OHSS prevention and reproductive outcomes on fresh IVF/intracytoplasmic sperm injection cycles, although more extensive studies are needed to draw firm conclusions.

In a recent retrospective study by Lin et al. [39], a total of 427 completed GnRHa-downregulated IVF cycles with fresh ET were enrolled. The results of that study suggested that dual triggering of final oocyte maturation with GnRHa and a standard dose of hCG can significantly improve live birth rates, clinical pregnancy rates, and the fertilization rate in women with diminished ovarian reserve undergoing GnRHa-downregulated IVF-intracytoplasmic sperm injection cycles. Clinical results of letrozole-COH efficiency in terms of oocyte quality and pregnancy outcomes in breast cancer patients are still limited, and large data sets will probably be available in several years. The first evaluation of the impact of letrozole-COH on the oocyte microenvironment in patients with breast cancer has suggested that a GnRHa trigger may improve oocyte quality [40].

However, Asada et al. [41] reported that the usual dose of GnRHa could fail to trigger oocyte maturation. They suggested that this finding may be attributable to a suboptimal endogenous LH surge due to the severe downregulation of the hypothalamus-pituitary axis. The researchers recommended that a rescue protocol entailing retriggering oocyte maturation using hCG could produce a successful outcome. Chen et al. [42] published a systemic review and meta-analysis that indicated comparable or significantly improved outcomes with the use of GnRH agonists in addition to hCG compared with hCG alone for the triggering of final oocyte maturation.

BRCA gene mutations and ovarian reserve

AMH is a sensitive serum marker that approximates the primordial follicle reserve. Titus et al. [43] compared serum AMH concentrations in young breast cancer patients (n=84) with (n=24 per group; mean age, 34.8±4.8 years) and without (n=60 per group; mean age, 36.3±3.5 years) BRCA mutations. The patients with mutations displayed significantly lower serum concentrations of AMH than the patients without them (1.22±0.92 ng/mL vs. 2.23±1.56 ng/mL, respectively; p<0.001). When the researchers analyzed the impact of BRCA1 versus BRCA2 mutations on ovarian reserve compared to those who tested negative for the same mutations (n=60 per group; mean age, 36.3±3.5 years), the significance remained for BRCA1 mutations (n=15 per group; two patients had both BRCA1 and BRCA2 mutations; mean AMH concentration, 1.12±0.73 ng/mL; p<0.0001) but not for BRCA2-only mutations (n=9 per group; mean AMH concentration, 1.39±1.20; p=0.127). The researchers used transgenic mouse models to confirm that women with BRCA1 mutations had diminished ovarian reserve. The data are also consistent with the decreased response to ovarian stimulation and earlier menopausal age shown previously in human BRCA1 mutation carriers [43].

Recently, Peccatori et al. [44] suggested that individuals with BRCA1 mutations have significantly lower mature oocyte yields. This independence of the role of BRCA1 mutations was confirmed by the comparison of this study group with a group of patients without BRCA mutations who were being treated for breast cancer. Oocyte cryopreservation is a feasible option that should be suggested to these patients, especially considering the frequent recommendation of prophylactic bilateral salpingo-oophorectomy at the age of 40 for both women with BRCA1 mutations and those with BRCA2 mutations.

In contrast, a retrospective cohort study demonstrated that BRCA carriers with and without malignancy had comparable ovarian reserve and response to ovarian stimulation to noncarriers undergoing fertility preservation [45]. However, data from Korean patients indicated that breast cancer patients with BRCA mutations had significantly lower serum AMH levels, although no significant differences were found between those with BRCA1 and those with BRCA2 mutations. The researchers recommended that fertility preservation be considered more aggressively in young breast cancer patients with BRCA mutations [46].

Winship et al. [47] published the protocol for a prospective observational study that will be the first large-scale study aimed at exploring the measurement of ovarian reserve in both BRCA1 and BRCA2 mutation carriers compared with age-matched patients without these mutations. The results of this study have the potential to clarify the association between circulating AMH and follicle density and thus help elucidate the mechanism of oocyte loss during reproductive life, particularly for women who are thought to have reduced ovarian reserve, such as BRCA mutation carriers.

Women with BRCA mutations (in consideration of the differences between BRCA1 and BRCA2 mutations) may be informed about the possible advantages of oocyte cryopreservation, along with the general risks, cost, and effectiveness of the procedure. Putting aside the unresolved debate on the impact of BRCA mutations on ovarian reserve, a personalized assessment of serum AMH or antral follicle count at the time of counseling can also be useful. Based on current knowledge, standardized clinical management cannot be recommended. However, even if a policy of fertility preservation in young, healthy BRCA carriers cannot be advocated across the board, it deserves consideration and should be carefully discussed on an individual basis [48].

Further research on the impact of BRCA mutations on fertility is necessary to confirm these findings and provide a better understanding of the underlying pathophysiology. Given that conflicting evidence exists regarding diminished fertility in this specific population, larger prospective trials are required to clarify the impact of BRCA mutations on ovarian aging.

Conclusion

In Korea, requests for fertility preservation treatment in breast cancer patients are becoming increasingly common. Random-start COH and dual ovarian stimulation with the co-administration of letrozole are feasible for the efficient harvest of oocytes or embryos and the reduction of the total duration of fertility preservation treatment, and these techniques work without raising peak estradiol levels and correspondingly increasing breast cancer risk. The use of a GnRHa trigger may improve cycle outcomes in breast cancer patients undergoing fertility preservation. In young breast cancer patients with BRCA mutations, particularly BRCA1 mutations, more effective fertility preservation treatment should be considered. The COH protocol for fertility preservation in women with breast cancer is outlined in Figure 1. Additional clinical studies with larger samples are required to confirm the optimal protocol for fertility preservation in young women with breast cancer.

Figure 1.

Controlled ovarian hyperstimulation protocol for fertility preservation in women with breast cancer. OPU, ovum pick-up; E2, estradiol; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; GnRHa, gonadotropin-releasing hormone agonist.